![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
ABSTRACT
Introduction: A first-in-class anticancer quinolone derivative with topoisomerase II activity, mechanistically, vosaroxin is similar to the anthracycline class. However, vosaroxin displays advantageous pharmacokinetic properties such as minimal metabolism, a lack of free radical production, is not a substrate for the P glycoprotein efflux pump, and can exert its antineoplastic activity independently of P53 function. Vosaroxin has shown encouraging results when combined with cytarabine in older patients with relapsed or refractory acute myeloid leukemia (AML) while balancing early toxicity and mortality, making it a compelling novel therapy for acute myelogenous leukemia.
Areas covered: Herein, we review the clinical data from published and internationally presented clinical trials utilizing vosaroxin for AML in the elderly, and relapsed and refractory population. Pivotal trials reviewed include the multicenter, phase II, REVEAL-1 study of single-agent vosaroxin in untreated elderly patients and the multicenter, phase III, VALOR study of vosaroxin in combination with intermediate dose cytarabine for patients with relapsed or refractory AML.
Expert opinion: Outcomes for older adults with AML, and for patients with relapsed or refractory disease are persistently poor. Improvement in outcomes in the elderly population highlight the utility of this agent in a difficult to treat, often more resistant and intolerant to therapy, group of patients. The expected and observed lack of cardiotoxicity makes this drug particularly suitable for the older population, especially those that may have received prior anthracycline based therapy.
Declaration of interest
F Ravandi has received research funding and honoraria from Sunesis, as well as participating in their advisory committee. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.